Clinical Application of Iodine-125 Seed Brachytherapy Combined with Anti–PD-1 Antibodies in the Treatment of Lung Cancer

Sui, Aixia; Song, Haiyan; Yu, Haojun; Zhang, Hongtao; Hu, Qilu; Lei, Yuying; Zhang, Lijuan; Wang, Juan

doi:10.1016/j.clinthera.2020.05.018

Cited by 4 publications

(3 citation statements)

References 14 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Also, in the present study, the number of I-125 particles was not analyzed and serves as a limitation. Currently, the advances in CT-imaging and post-processing can enable the determination of particle number, spatial arrangement and activity [ 35 ]. Here we did not make a detailed study of seed migration.…”

Section: Discussionmentioning

confidence: 99%

CT-MR Image Fusion for Post-Implant Dosimetry Analysis in Brain Tumor Seed Implantation- a Preliminary Study

et al. 2022

View full text Add to dashboard Cite

Purpose. To calculate and evaluate postimplant dosimetry (PID) with CT-MR fusion technique after brain tumor brachytherapy and compare the result with CT-based PID. Methods and Materials. 16 brain tumor patients received MR-guided intervention with Iodine-125 (125I) seed implantation entered this preliminary study for PID evaluation. Registration and fusion of CT and MR images of the same patients were performed one day after operation. Seeds identification and targets delineation were carried out on CT, MR, and CT-MR fusion images, each. The number and location of seeds on MR or CT- MR fusion images were compared with those of actually implanted seeds. Clinical target volume (CTV) and dosimetric parameters such as %D90, %V100 and external V100 were measured and calculated. In addition, the correlation of the fusion to CT CTV ratio and other factors were analyzed. Results. The numbers of fusion seeds were not significantly different compared with reference seeds (t =1.76, p >0.05). The difference between reference seeds numbers and truly extracted MR seeds numbers was statistically significant (t =3.91, p <0.05). All dosimetric parameters showed significant differences between the two techniques (p <0.05). The mean CTV delineated on fusion images was 34.3 ± 33.6, smaller than that on CT images. The mean values of external V100, %V100 and %D90 on fusion images were larger than those on CT images. Correlation analysis showed that the fusion-CT V100 ratio was positively and significantly correlated with the fusion-CT volume ratio. Conclusions. This preliminary study indicated that CT-MR fusion-based PID exhibited good accuracy for 125I brain tumor brachytherapy dosimetry when compared to CT-based PID and merits further research to establish best-outcome protocols.

show abstract

Section: Discussionmentioning

confidence: 99%

CT-MR Image Fusion for Post-Implant Dosimetry Analysis in Brain Tumor Seed Implantation- a Preliminary Study

et al. 2022

View full text Add to dashboard Cite

show abstract

“…A meta‐analysis including 1 188 cases showed that the combination of iodine‐125 brachytherapy and chemotherapy significantly improved the OS and clinical efficacy for advanced NSCLC with no difference in complications 32 . Sui et al reported encouraging results using iodine‐125 brachytherapy and anti‐PD‐1 antibodies for lung cancer 33 …”

Section: Discussionmentioning

confidence: 99%

“…32 Sui et al reported encouraging results using iodine-125 brachytherapy and anti-PD-1 antibodies for lung cancer. 33 The key to success of iodine-125 brachytherapy for MLNMs was the accurate placement of the needles and seeds according to the preoperative plan. The complex mediastinal anatomy, especially the vital organs, such as the aorta, pulmonary artery and vein, and esophagus, must be taken into account when planning the puncture path and performing the procedure.…”

Section: Discussionmentioning

confidence: 99%

CT‐guided iodine‐125 brachytherapy as salvage therapy for recurrent mediastinal lymph node metastasis

et al. 2021

View full text Add to dashboard Cite

Background The treatment of recurrent mediastinal lymph node metastasis (MLNMs) is challenging. We conducted this study to evaluate the effectiveness and safety of computed tomography (CT)‐guided percutaneous iodine‐125 brachytherapy for MLNMs. Methods We retrospectively analyzed 33 patients with recurrent MLNMs treated with CT‐guided interstitial implantation of iodine‐125 seeds. Regular contrast‐enhanced CT was conducted to evaluate the tumor response. Follow‐up survival, quality of life, and adverse events were analyzed. Results The number of implanted seeds was 16–85 (median, 40). The matched peripheral dose was 110–160 Gy. The patients were followed up for 5–24 months (median, 14 months). At the last follow‐up or death, complete response to therapy was achieved in 11 patients (33.3%) and partial response in 18 patients (54.5%). The median survival time of this cohort was 15.2 months (95% confidence interval [CI], 9.9–20.5 months); the estimated one‐ and two‐year survival rates were 68.6% and 31.1%, respectively. The Karnofsky performance score increased significantly after the procedure (p = 0.007). Pneumothorax with pulmonary compression of 30% to 40% occurred in five (15.2%) patients and was cured after drainage. No severe complications occurred. Conclusions CT‐guided iodine‐125 brachytherapy provided a safe and effective choice for recurrent mediastinal lymph node metastasis with significant local therapeutic effects and minor complications, especially for patients who were not eligible for surgical resection and had failed to benefit from systemic therapy.

show abstract

Iodine-125/nivolumab/pembrolizumab

2020

Reactions Weekly

View full text Add to dashboard Cite

Clinical Application of Iodine-125 Seed Brachytherapy Combined with Anti–PD-1 Antibodies in the Treatment of Lung Cancer

Cited by 4 publications

References 14 publications

CT-MR Image Fusion for Post-Implant Dosimetry Analysis in Brain Tumor Seed Implantation- a Preliminary Study

CT-MR Image Fusion for Post-Implant Dosimetry Analysis in Brain Tumor Seed Implantation- a Preliminary Study

CT‐guided iodine‐125 brachytherapy as salvage therapy for recurrent mediastinal lymph node metastasis

Iodine-125/nivolumab/pembrolizumab

Contact Info

Product

Resources

About